Arcturus

Messenger RNA
Biotech

Arcturus doubles down on mRNA, axes several early-stage assets

Analysts said the discontinued programs—mRNA vaccines for chlamydia, gonorrhea and Lyme disease—had “low [return on investment] visibility.”
Ben Adams , Gabrielle Masson May 13, 2025 1:32pm
SARS-CoV-2

Arcturus falls as self-amplifying COVID jab posts 55% efficacy

Apr 20, 2022 8:45am